Clinical Assessment & Management of Prion Disease
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

Clinical Assessment & Management of Prion Disease

on

  • 694 views

 

Statistics

Views

Total Views
694
Views on SlideShare
518
Embed Views
176

Actions

Likes
0
Downloads
6
Comments
0

2 Embeds 176

http://www.cjdblogger.com 140
http://cjdblogger.squarespace.com 36

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Clinical Assessment & Management of Prion Disease Presentation Transcript

  • 1. Clinical Assessment & Management of Prion Disease Brian S. Appleby, M.D. Associate Professor Department of Neurology
  • 2. Objectives • Understand how clinicians diagnose prion disease • Describe tools used to diagnose prion disease • Provide update on clinical trials for prion disease
  • 3. “If it looks like a duck, quacks like a duck, then it’s probably a duck.” Dr. Edward Tsou (GUH) Horses versus Zebras
  • 4. Diagnostic Syndromes Pneumonia • Malaise • Cough • Fever • Chest/back pain • Shortness of breath Creutzfeldt-Jakob disease (CJD) • • • • • • • Dementia Difficulty with gait Incoordination Abnormal movements Weakness Visual disturbances Rapid progression
  • 5. What Clinicians See Appleby BS et al, Arch Neurol 2009 Appleby BS et al, Arch Neurol 2009
  • 6. Initial Diagnoses Appleby BS et al, Prion 2008
  • 7. #1 Rule for Diagnosing Prion Disease Prion Disease
  • 8. Why? • Consequences of missing other diagnoses – Treatable – Reversible – Different Prognosis – Repeated work-ups later – Difficulty in accepting different diagnosis
  • 9. Probable Sporadic CJD ≥2 Clinical Signs • Dementia • Visual or cerebellar • Pyramidal or extrapyramidal • Akinetic mutism ≥ 1 Diagnostic Test Result • CSF 14-3-3 and <2 yrs duration • PSWC’s on EEG • Brain MRI findings Zerr I et al, Brain 2009
  • 10. Conditions with CSF 14-3-3 • TBI • Seizures Berg D et al, Nat Rev Neurosci 2003
  • 11. EEG CJD Non-CJD Total PSWC’s 10 2 12 No PSWC’s 5 12 17 PSWC’s Steinhoff BJ et al, Arch Neurol 1996
  • 12. EEG Parchi P et al, Ann Neurol 1999
  • 13. ≥ 1 of the Following (FLAIR and/or DWI) • High signal abnormality in basal ganglia • High signal abnormality in ≥ 2 cortical regions • Temporal • Parietal • Occipital Frontal Zerr I et al, Brain 2009
  • 14. Brain MRI Zerr I et al, Brain 2009
  • 15. Hamlin C et al, Neurology 2012
  • 16. “Forest through the Trees”
  • 17. Case Example • 61 y.o. WF from St. Maarten’s Island with a history of alcohol abuse • 2 mo. h/o ataxia, apathy, myoclonus, and cognitive impairment • Vitamin B12=249, folate=8.6, MCV=98
  • 18. Exam General: Vacant look, utilization behavior Speech: Dysarthric, apraxic, latent Thought Content: Appeared to be responding to visual hallucinations MMSE: 12/30 Motor: Mild rigidity UE (L>R), myoclonus Gait: Ataxic, requires 2 person assist, dysmetria (L>R)
  • 19. Brain MRI (DWI)
  • 20. Experimental Treatment Compound • Quinacrine • Pentosan polysulphate • Doxycycline Outcome • no effect • may have effect in vCJD • verdict is unclear
  • 21. Individuals with less impairment and better functioning chose quinacrine Individuals with more impairment and less functioning declined quinacrine Only 2 of 107 subjects chose randomization Collinge J et al, Lancet Neurol 2009
  • 22. “On the basis of the available evidence, the best possible outcome that could be expected after treatment with intraventricular PPS is that there may be some temporary slowing or halting of the disease progression. However, there is little likelihood of significant clinical improvement. Nor is there a likelihood of permanent halting of disease progression.” CJD Support Network Newsletter, March 2004
  • 23. German Observational Study Group Number of cases Median survival time Doxycycline treated 21 292 days Untreated (historical cntrl) 581 169 days Log Rank test, p<0.001 p=0.019 PRNP codon 129 polymorphism Zerr I, Prion 2008, Madrid, Spain
  • 24. Symptomatic Treatment Symptom Suggested Treatment Psychosis/Agitation Low potency neuroleptics (e.g., quetiapine) Myoclonus/Hyperstartle Long acting benzodiazepines (e.g., diazepam) Anticonvulsants (e.g., valproic acid) Seizures Anticonvulsants Dystonia/Contractures Passive movement Long acting benzodiazepines, Botulinum toxin injections Constipation Bowel regimen (e.g., dulcolax) Dysphagia/Rumination Thickener, cueing Behavioral/Environmental changes first Start low and go slow Re-evaluate frequently
  • 25. Thank You • Patients and families • CJD Foundation • National Prion Disease Pathology Surveillance Center • CJD Support Group Network